Shilpa Medicare Limited has informed the Exchange about execution of definitive agreement by Koanna International FZ LLC, UAE a wholly owned subsidiary of Shilpa Medicare Limited with Pharma Pharmaceutical Industries & Biological Products (PPI), a prominent Saudi enterprise
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare's wholly owned UAE subsidiary Koanna International FZ LLC has signed a definitive agreement with Saudi Arabia's Pharma Pharmaceutical Industries & Biological Products (PPI) to form a new joint venture company in the Kingdom of Saudi Arabia. The JV will be owned 70% by PPI and 30% by Koanna, and will set up a new pharmaceutical manufacturing facility. The rollout is in two phases: Phase 1 involves Koanna supplying finished formulations in bulk for repackaging at the new facility, and Phase 2 involves full technology transfer from Shilpa for local manufacturing of finished products. Shilpa will also handle the regulatory filings with the Saudi Food and Drug Authority. The company stated the JV is aimed at strengthening Shilpa's global footprint and consolidating its presence in the MENA region, aligned with Saudi Arabia's Vision 2030 goals.
This is a strategic expansion move for Shilpa Medicare into the Saudi and broader MENA market with a local partner, which could open new revenue streams over the medium term. For shareholders, it signals international growth ambition, though the 30% minority stake means limited financial contribution in the near term and execution and regulatory risks remain.